Activities Report and App 4C for quarter ended 31 March 2021
Filed with ASX · · 10 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Japanese Renal Cancer Imaging Trial Meets Study Objectives
- Launch of International NOBLE Registry for SPECT Imaging
- TGA commences priority evaluation process for Illuccix
- S&P DJI Announces March 2021 Quarterly Rebalance
- Appendix 4E - Results for announcement to the market
Later from Telix Pharmaceuticals
- Phase III Prostate Cancer Therapy Clinical Trial Commences
- German Distribution Agreement with Eckert and Ziegler
- TLX66 Meets Study Objectives in Patients with AL Amyloidosis
- US Co-Promotion with EZAG for Prostate Cancer Imaging
- Update on FDA New Drug Application Review for Illuccix
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals